Ed Kaye is tak­ing his fledg­ling biotech to Wall Street, look­ing for a new in­jec­tion of cash

Ed Kaye should soon be back to run­ning a pub­lic biotech. 

The Stoke Ther­a­peu­tics CEO, who cut short a brief break af­ter his ex­it from Sarep­ta to run the fledg­ling start­up and un­veil a lean $40 mil­lion launch round pri­mar­i­ly from Ap­ple Tree Part­ners, has steered an S-1 to the SEC. And he’s pen­ciled in a $86 mil­lion raise, look­ing for Wall Street to fund their last steps through pre­clin­i­cal work on a lead pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER